JP2018531965A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531965A5
JP2018531965A5 JP2018521617A JP2018521617A JP2018531965A5 JP 2018531965 A5 JP2018531965 A5 JP 2018531965A5 JP 2018521617 A JP2018521617 A JP 2018521617A JP 2018521617 A JP2018521617 A JP 2018521617A JP 2018531965 A5 JP2018531965 A5 JP 2018531965A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable composition
agent
therapeutic agent
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521617A
Other languages
English (en)
Japanese (ja)
Other versions
JP7088473B2 (ja
JP2018531965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059697 external-priority patent/WO2017075580A1/en
Publication of JP2018531965A publication Critical patent/JP2018531965A/ja
Publication of JP2018531965A5 publication Critical patent/JP2018531965A5/ja
Priority to JP2022087580A priority Critical patent/JP2022105767A/ja
Application granted granted Critical
Publication of JP7088473B2 publication Critical patent/JP7088473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521617A 2015-10-29 2016-10-31 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 Active JP7088473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022087580A JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248163P 2015-10-29 2015-10-29
US62/248,163 2015-10-29
PCT/US2016/059697 WO2017075580A1 (en) 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022087580A Division JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018531965A JP2018531965A (ja) 2018-11-01
JP2018531965A5 true JP2018531965A5 (cg-RX-API-DMAC7.html) 2019-12-12
JP7088473B2 JP7088473B2 (ja) 2022-06-21

Family

ID=57233968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521617A Active JP7088473B2 (ja) 2015-10-29 2016-10-31 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
JP2022087580A Pending JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022087580A Pending JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Country Status (7)

Country Link
US (2) US20170119899A1 (cg-RX-API-DMAC7.html)
EP (1) EP3368088B1 (cg-RX-API-DMAC7.html)
JP (2) JP7088473B2 (cg-RX-API-DMAC7.html)
CN (1) CN108430514B (cg-RX-API-DMAC7.html)
AU (1) AU2016343855B2 (cg-RX-API-DMAC7.html)
CA (1) CA3003589C (cg-RX-API-DMAC7.html)
WO (1) WO2017075580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019118951A2 (en) * 2017-12-15 2019-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
CN112955150A (zh) * 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
WO2020142373A1 (en) * 2019-01-02 2020-07-09 Mayo Foundation For Medical Education And Research Methods and materials for treating leukodystrophies
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
JP2023522984A (ja) * 2020-04-24 2023-06-01 アシュバッタ セラピューティクス, インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
PH12023550133A1 (en) * 2020-07-17 2024-06-24 Ashvattha Therapeutics Inc Dendrimer compositions and methods for drug delivery to injured kidney
WO2023081750A1 (en) * 2021-11-04 2023-05-11 The Children's Hospital Of Philadelphia Compositions and methods for treating metachromatic leukodystrophy disease and related disorders
US20260103728A1 (en) * 2022-10-12 2026-04-16 The Johns Hopkins University Method of treating lbsl by enhancing dars2 expression
CN116082153A (zh) * 2022-12-09 2023-05-09 长沙贝塔医药科技有限公司 一种丙烯酸酯类衍生物-13c的制备方法
EP4410284A1 (en) * 2023-02-02 2024-08-07 Apteeus Compound and method for the treatment of zellweger spectrum disorder
CN117643581A (zh) * 2023-11-29 2024-03-05 徐州医科大学 白藜芦醇在制备激活sirt1基因的药物中的应用
US20250352653A1 (en) * 2024-05-14 2025-11-20 Washington State University Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6355677B1 (en) * 1998-09-28 2002-03-12 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
CN101495152A (zh) * 2006-05-22 2009-07-29 艾伦药物公司 通过三信反应制备作为vla-4拮抗剂的聚合物结合物的方法
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
CA2767163A1 (en) * 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
AU2014276379A1 (en) * 2013-06-07 2016-01-07 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
CN105813690A (zh) * 2013-08-21 2016-07-27 协和大学 树状聚合物-白藜芦醇复合物
WO2016025745A1 (en) * 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders

Similar Documents

Publication Publication Date Title
Sun et al. Promotion of astrocyte-neuron glutamate-glutamine shuttle by SCFA contributes to the alleviation of Alzheimer's disease
Cepeda et al. The role of dopamine in Huntington's disease
Ward et al. Neurodegenerative diseases and therapeutic strategies using iron chelators
CN102764279B (zh) 改变细胞功能的方法和组合物
US20110008466A1 (en) Methods and compositions for altering cell function
US20110038889A1 (en) Methods and compositions for altering cell function
Abdel-Salam Drugs used to treat Parkinson's disease, present status and future directions
US10716866B2 (en) Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
US8865763B2 (en) Methods and compositions for altering cell function
Yamamoto et al. Pallido-nigro-luysian atrophy, progressive supranuclear palsy and adult onset Hallervorden-Spatz disease: a case of akinesia as a predominant feature of parkinsonism
Shaw Dopamine excess and/or norepinephrine and epinephrine deficiency in autistic patients due to prenatal and/or postnatal deficiency of dopamine beta-hydroxylase
Takeda et al. Intrastriatal grafts of fetal ventral mesencephalon improve allodynia-like withdrawal response to mechanical stimulation in a rat model of Parkinson's disease
Latimer Tardive dyskinesia: a review
US8871715B2 (en) Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20070155687A1 (en) Methods and compositions for altering cell function
Lv et al. Research progress of kynurenine pathway in Alzheimer's disease.
AU2013205053B2 (en) Method and compositions for altering cell function
CA2524551C (en) Use of selenium yeasts in the treatment of alzheimer's disease
Ogawa et al. Parkinson’s disease, dopamine and free radicals
Zerihun et al. Stem Cell Therapy for Parkinson's Disease: Past, Present and Future
Munhoz et al. P3. 023 Parakinesia Brachialis Oscitans due to brainstem stroke. Report of two cases
De Marchi et al. Co-occurrence of OCD and HD in a nuclear family
Guiloff Motor neurone disease
Impairment et al. Diffusion Tensor Mr Imaging for Evaluation of Fronto-Subcortical Neural Pathway Changes in Parkinson's Disease With Dementia